Anti-Tryptase CE/IVD antibodies for immunohistochemistry (IHC) are established diagnostic reagents used in hematopathology for the identification and visualization of mast cells in formalin-fixed, paraffin-embedded (FFPE) tissue sections. Their clinical relevance is supported by extensive peer-reviewed literature describing tryptase as a mast cell–associated serine protease involved in inflammatory and hypersensitivity-related biological processes. In regulated diagnostic settings, tryptase immunostaining contributes to the assessment of mast cell distribution and burden in tissue biopsies.

Biological significance of tryptase (TPSAB1/TPSB2-related serine proteases)

• Tryptase is a major neutral serine protease stored in mast cell secretory granules and released upon cellular activation and degranulation. In humans, mast cell tryptases are primarily encoded by the TPSAB1 and TPSB2 genes.
• Expression in diagnostic tissue contexts is largely restricted to mast cells, supporting its use as a lineage-associated marker in histopathology.
• Biologically, tryptase is involved in proteolytic processing events contributing to inflammatory signaling, modulation of vascular permeability, extracellular matrix remodeling, and activation of protease-sensitive pathways relevant to allergic and hypersensitivity reactions, including anaphylaxis.

Diagnostic utility in hematopathology

• In routine diagnostic practice, tryptase immunohistochemistry is used to support the detection and localization of mast cells in tissue specimens, including bone marrow, skin, and gastrointestinal biopsies.
• It is applied as part of the immunophenotypic evaluation of suspected mast cell proliferations, including systemic mastocytosis, in conjunction with established histopathological and clinical criteria.
• Serum tryptase measurement is also used as a complementary laboratory parameter reflecting mast cell burden and/or activation and represents a minor criterion in internationally recognized diagnostic frameworks for systemic mastocytosis.
• Its combined tissue and laboratory utility supports its translational relevance in hematopathology workflows.

Key features of CE/IVD Anti-Tryptase antibodies for IHC

• CE/IVD-labeled anti-tryptase antibodies are intended for use in validated in vitro diagnostic workflows on FFPE tissue sections.
• They are designed to support consistent and reproducible immunohistochemical staining under standardized laboratory conditions in regulated environments.
• High analytical specificity for mast cell tryptase with low background staining under validated protocols.
• Robust cytoplasmic staining of mast cells across a range of tissue types.
• Compatibility with manual and automated immunohistochemistry platforms.
• Suitability for hematopathology applications, including bone marrow, lymphoid, and cutaneous specimens.
• Compliance with CE/IVD regulatory requirements for in vitro diagnostic use in appropriate laboratory settings.